- ORY1001
-
- $54.00 / 1mg
-
2025-07-15
- CAS:1431326-61-2
- Min. Order:
- Purity: 99.85%
- Supply Ability: 10g
- LSD1-IN-1
-
- $0.10 / 1KG
-
2020-04-25
- CAS:1431326-61-2
- Min. Order: 1KG
- Purity: 99.0%
- Supply Ability: 1000 tons
- LSD1-IN-1
-
- $0.00 / 1Kg
-
2020-02-26
- CAS: 1431326-61-2
- Min. Order: 1KG
- Purity: 99.0%+
- Supply Ability: 100 tons
|
| | LSD1-IN-1 Basic information |
| Product Name: | LSD1-IN-1 | | Synonyms: | rel-N1-[(1R,2S)-2-Phenylcyclopropyl]-1,4-cyclohexanediamine hydrochloride (1:2);LSD1-IN-1;ORY-1001;ORY-1001 (RG-6016);RG 6016;ORY-1001 2HCl salt;RG 6016;RG6016;RG-6016;ORY1001;ORY 1001;ORY-1001 trans and cis isomers | | CAS: | 1431326-61-2 | | MF: | C15H24Cl2N2 | | MW: | 303.27046 | | EINECS: | | | Product Categories: | | | Mol File: | 1431326-61-2.mol |  |
| | LSD1-IN-1 Chemical Properties |
| storage temp. | Store at -20°C | | solubility | insoluble in EtOH; ≥23.15 mg/mL in H2O; ≥6.9 mg/mL in DMSO with gentle warming | | form | solid | | CAS DataBase Reference | 1431326-61-2 |
| | LSD1-IN-1 Usage And Synthesis |
| Description | Lysine-specific demethylase 1 (LSD1) demethylates H3K4 and H3K9, resulting in transcriptional repression. It also controls the tumor suppressor activity of p53 by demethylating a specific p53 lysine residue (LYS370). ORY-1001 is an orally available, selective inhibitor of LSD1 (IC50 < 20 nM). It targets acute myeloid leukemia (AML) stem cells and significantly reduces tumor cell load while increasing survival time in mouse models of AML. ORY-1001 is in clinical trials for cancer treatment. | | Uses | ORY-1001 is a potent LSD1 inhibitor. | | in vitro | ory-1001 is an enantiomerically pure kdm1a inhibitor with high selectivity against related fad dependent aminoxidases. ory-1001 does not inhibit non-related histone modifiers, and is clean in a cerep diversity panel. treatment of thp-1 cells with ory-1001, results in a time/dose dependent me2h3k4 accumulation at kdm1a target genes and concomitant induction of differentiation markers [1]. | | in vivo | daily oral administration of doses < 0.020 mg/kg leads to significantly reduced tumor growth in rodent xenografts. in vivo studies have shown that ory-1001 presents excellent oral bioavailability, target exposure and activity in vivo [1]. | | IC 50 | <20nm |
| | LSD1-IN-1 Preparation Products And Raw materials |
|